Powering Tissue Factories

We make tissue manufacturing reproducible at every scale, from a single bench to autonomous labs.

WITHIN TOLERANCE Human tissue model Site ASite BSite C Capitula: one platform across every step

Demand for human tissue models is growing fast

Drug developers and clinical teams need human tissue, not animal proxies, at production volume. The field is accelerating toward better preclinical models.

  1. 2019EPA · plan to phase out animal testing by 2035
  2. 2021EU Parliament · resolution to phase out animal testing
  3. 2022FDA Modernization Act 2.0
  4. 2025FDA · Roadmap to Reducing Animal Testing
  5. 2025NIH · prioritizing non-animal methods
  6. 2026FDA Modernization Act 3.0
  7. OngoingEU · New Approach Methodologies Roadmap

The tools were built for experiments, not manufacturing

Today the data never connects. Build files, paper notebooks, bioink logs, quality analysis, and assay results are stitched together, so they're difficult to search, communicate, and reproduce.

Paper notebook Build instructions Quality analysis Assay results Bioink & process log No shared record

Now every step writes to the same record

Five modules cover the workflow, coordinate to predict. Each one replaces a manual step that used to end in a file nobody else could open, and each writes to the same structured record instead.

Drug discovery has been here before

After the 1962 Kefauver-Harris Amendment raised the evidentiary bar, the industry reorganized around structured, reproducible data. High-throughput screening only became possible because decades of consistent records and standardized compounds existed to screen.

1962 2022 Safety and efficacy No animal testing requirement Kefauver-Harris Structured records HTP screening In silico models FDA Modernization Structured records Preclinical models In silico models

We are on the verge of a preclinical model revolution, and like the last one it will be built on a structured record of every design, process and result.

Reproducibility makes manufacturing possible

Capitula spans the whole workflow, from preparation through analysis.

CAPITULA Preparation Biofabricator Analysis

Start standardizing your workflow now

Scaled tissue manufacturing starts with reproducible data, and that starts with your next build. Capitula is built and shipping now.